Serina Therapeutics, Inc.

SER NYSE CIK: 0001708599

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation AL
Business Address 601 GENOME WAY, HUNTSVILLE, AL, 35806
Mailing Address 601 GENOME WAY, HUNTSVILLE, AL, 35806
Phone (256) 327-9630
Fiscal Year End 1231
EIN 821436829

Financial Overview

FY2024

$6.22M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report February 3, 2026 View on SEC
S-3 Shelf registration for future offerings January 30, 2026 View on SEC
4 Insider stock transaction report January 29, 2026 View on SEC
8-K Current report of material events January 28, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 21, 2026 View on SEC
8-K Current report of material events January 15, 2026 View on SEC
4 Insider stock transaction report January 14, 2026 View on SEC
4 Insider stock transaction report January 9, 2026 View on SEC
4 Insider stock transaction report December 29, 2025 View on SEC

Material Events

8-K Financial Distress January 15, 2026
High Impact
  • Opportunity to submit a detailed plan by February 8, 2026, to regain compliance with NYSE American listing standards.
  • Potential for an 18-month 'Cure Period' until July 9, 2027, if the recovery plan is accepted, allowing continued trading.
View Analysis
8-K Other December 10, 2025
High Impact
  • Serina Therapeutics submitted a complete response to the FDA regarding a clinical hold on its lead drug program, SER-252, for advanced Parkinson's disease.
  • The clinical hold, issued by the FDA, had paused human trials due to serious questions or concerns, likely about safety or trial design.
View Analysis

Insider Trading

SELL 1 insiders 20 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.